TICKERNERD
Menu
NNVCNNVCHealthcare · Biotechnology

NNVC Stock Forecast: NanoViricides, Inc. Price Predictions for 2026-2027

Last close, 15 Oct 2026
$1.37
+4.58% on the day

The 2 Wall Street analysts covering NanoViricides, Inc. hold a median 12-month price target of $6 — +338.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$33.4M
Ticker Nerd rank
61 / 100
Median analyst target
$6.00
Analysts covering
2
Revenue$0.0
Operating income−$2.0M
Net income−$2.0M
Free cash flow−$1.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.6%
1M
+30.5%
YTD
+21.2%
1Y
−4.9%
From 52W high
−32.5%
From 52W low
+61.2%
$0.85
$2.03
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NNVC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NanoViricides, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Growth
75
Value
65
Volatility
61
Accruals
59
Momentum
51
Revisions
49
Quality
34
Issuance
33

Size (84): Smaller than most of the companies we track.

Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NNVC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NNVC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26NNVCHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits +338.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 July 2026Noble Capital MarketsInitiatesOutperform—
7 May 2024EF HuttonReiteratesBuy—
16 Feb 2024EF HuttonReiteratesBuy—
1 June 2023EF HuttonAssumesBuy$5.25
18 Apr 2023EF HuttonReiteratesBuy—
28 Feb 2023EF HuttonMaintainsBuy$8.50 → $5.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NNVC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NNVC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Oct 2026, NanoViricides, Inc. returned −4.9% against +17.3% for the S&P 500, dividends included.

NNVC vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26NNVCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NNVC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

NanoViricides, Inc. (NNVC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
3.5×

Cheaper than 28% of US stocks

EV / EBITDA
−3.9×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−101.5%

Higher than 13% of US stocks

Return on assets
−55.5%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NanoViricides, Inc. (NNVC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NanoViricides, Inc. has a market value of $33.4M and an enterprise value of $30.6M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$8.1M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$7.4M, after $95K of capital spending.

  • Shares outstanding: 21.6M.

  • Trailing P/E: −2.1×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • NanoViricides, Inc. employs 7 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

NNVC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NNVCNanoViricides, Inc.$33.4M
61
BCTXBriaCell Therapeutics Corp.$33.7M
—
ALGSAligos Therapeutics, Inc.$32.4M
75
MGXMetagenomi Therapeutics, Inc.$32.3M
30
CRVOCervoMed, Inc.$34.6M
31
FLNAFilana Therapeutics, Inc.$35.3M
63
LITSLite Strategy, Inc.$35.6M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NanoViricides, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NNVC news & analysis

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

Accesswire · 13 Oct 2026positive

NanoViricides said its Phase IIA clinical trial of NV-387 oral gummies for Ebola is progressing well. The trial is evaluating different dosage regimens for varying severity levels of Ebola Bundibugyo infection and disease during the current outbreak in the Democratic Republic of Congo.

Why it matters — The update concerns progress in NNVC’s clinical evaluation of an oral treatment for Ebola.

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Accesswire · 5 Oct 2026neutral

NanoViricides provided additional details on its Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo. The company stated the trial is proceeding as designed, amid an ongoing outbreak that has claimed over 4,000 lives.

Why it matters — This update offers NNVC watchers insight into the progress and status of the company's Phase II Ebola treatment trial during an active outbreak.

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

Accesswire · 29 Sept 2026neutral

NanoViricides, Inc. announced it filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the SEC on September 28, 2026. The Company noted that its broad-spectrum antiviral candidate NV-387 is in Phase II clinical trials.

Why it matters — The filing provides NNVC watchers with the company's audited full-year financial results and an update confirming that its lead antiviral candidate NV-387 is advancing in Phase II clinical trials.

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

Accesswire · 28 Sept 2026positive

NanoViricides announced that its Phase II clinical trial of the oral drug NV-387, given as gummies for treating Bundibugyo Ebolavirus and other Ebola viruses, has begun enrolling and dosing patients at an Ebola Treatment Center in the DRC's Ituri province last week (on or about September 23rd). The trial is registered in the Pan African Clinical Trials Registry.

Why it matters — For NNVC watchers, this marks the start of patient enrollment and dosing in a pivotal Phase II Ebola trial, advancing the company's lead oral antiviral candidate into real-world clinical evaluation.

FAQ

Frequently asked questions about NNVC stock

What is the NNVC stock price forecast for 2026-2027?

The 2 Wall Street analysts covering NanoViricides, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NNVC stock a buy right now?

Of the 2 analysts covering NanoViricides, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NanoViricides, Inc. 61 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NNVC?

As at 14 Oct 2026, NanoViricides, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will NNVC stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +338.0% from the last close, and Ticker Nerd's factor model ranks NanoViricides, Inc. 61 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NNVC stock forecast for 2030?

No analyst covering NanoViricides, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NNVC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has NNVC stock performed over the past year?

NanoViricides, Inc. returned -4.9% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NanoViricides, Inc. do?

NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform.

What is the latest news on NNVC?

The most recent item we track (Accesswire, 13 Oct 2026): "Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides". NanoViricides said its Phase IIA clinical trial of NV-387 oral gummies for Ebola is progressing well. The trial is evaluating different dosage regimens for varying severity levels of Ebola Bundibugyo infection and disease during the current outbreak in the Democratic Republic of Congo.

Company

About NanoViricides, Inc.

NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to target and neutralize virus particles before they infect healthy cells. Its lead candidate, NV-387, is being developed for multiple viral infections, including respiratory viruses and other high-priority infectious diseases. NanoViricides also maintains additional antiviral programs addressing conditions such as herpes and other viral threats. The company combines drug discovery, development, and commercialization capabilities within a single business model, supporting its efforts across research, preclinical work, and clinical development. Headquartered in Shelton, Connecticut, NanoViricides occupies a niche position in the healthcare market as a developer of specialized antiviral treatments aimed at complex viral diseases.

CEO Dr. Anil R. Diwan Ph.D. · 7 employees · United States · https://www.nanoviricides.com